GH Research Q3 net loss narrows as costs fall

By Reuters News


Overview

  • Biopharma firm's Q3 net loss narrowed yr/yr as R&D and G&A expenses declined

  • Company ended Q3 with $350.6 mln in cash, cash equivalents and marketable securities

  • Company received positive initial FDA feedback on pivotal TRD program, expects End-of-Phase 2 meeting in Q1 2027


Outlook

  • GH Research expects End-of-Phase 2 FDA meeting for TRD program in Q1 2027

  • Company plans to initiate TRD pivotal program shortly after FDA meeting, pending alignment

  • GH Research targets PPD pivotal program initiation in H2 2027, subject to regulatory alignment


Result Drivers

  • LOWER R&D EXPENSES - Co said Q3 research and development expenses fell due to decreased technical and clinical development costs

  • LOWER G&A EXPENSES - Co said Q3 general and administrative expenses declined due to lower professional fees


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Loss Per Share

$0.18


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for GH Research PLC is $39.50, about 113.6% above its November 12 closing price of $18.49


Reuters Recommended Reads

  • Nov 12 - Fractyl Health's Q3 net loss narrows as costs fall, shifts focus to Revita

  • Nov 12 - Rocket Pharmaceuticals Q3 net loss narrows as R&D costs fall

  • Nov 12 - Prime Medicine Q3 loss narrows as expenses decline


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.